"IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)."

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

8500Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC. We report the primary disease-free surviv... Click to show full abstract

Keywords: chemotherapy; phase iii; impower010 primary; stage; results phase; primary results

Journal Title: Journal of Clinical Oncology
Year Published: 2021

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended